他汀类药物用于成人心血管疾病预防:美国预防服务工作组证据报告与系统综述
该系统综述纳入19项随机临床试验(n=71 344),评估他汀用于无既往心血管事件成人的获益与危害。他汀治疗与全因死亡、心血管死亡、卒中、心肌梗死及复合心血管结局风险降低相关,绝对获益在基线风险较高者更大;未增加严重不良事件、肌痛或肝脏相关危害风险,糖尿病风险总体无显著增加但存在异质性。
要点
- 他汀治疗与全因死亡风险降低相关(RR 0.86,95%CI 0.80-0.93)。
- 他汀治疗与心肌梗死风险降低相关(RR 0.64,95%CI 0.57-0.71)。
- 他汀未增加严重不良事件、肌痛或肝脏相关危害风险。
核心结论
- 在无既往心血管事件但心血管风险增高的成人中,他汀治疗与全因死亡、心血管死亡及心血管事件风险降低相关,基线风险较高者绝对获益更大。
研究设计与样本
- 系统综述与随机效应Meta分析,纳入19项随机临床试验,共71 344名参与者(范围95-17 802),平均年龄51-66岁,比较他汀与安慰剂或不他汀、固定剂量与滴定他汀、高强度与低强度他汀。
主要发现
- 他汀治疗与全因死亡风险降低相关(RR 0.86,95%CI 0.80-0.93;I²=0%;绝对风险差-0.40%,95%CI -0.64%至-0.17%)。
- 他汀治疗与心血管死亡风险降低相关(RR 0.69,95%CI 0.54-0.88;I²=54%;绝对风险差-0.43%,95%CI -0.75%至-0.11%)。
- 他汀治疗与卒中风险降低相关(RR 0.71,95%CI 0.62-0.82;I²=0;绝对风险差-0.38%,95%CI -0.53%至-0.23%)。
- 他汀治疗与心肌梗死风险降低相关(RR 0.64,95%CI 0.57-0.71;I²=0%;绝对风险差-0.81%,95%CI -1.19%至-0.43%)。
- 他汀治疗与复合心血管结局风险降低相关(RR 0.70,95%CI 0.63-0.78;I²=36%;绝对风险差-1.39%,95%CI -1.79%至-0.99%)。
关键数值与推荐
- 他汀未增加严重不良事件风险(RR 0.99,95%CI 0.94-1.04)。
- 他汀未增加肌痛风险(RR 0.96,95%CI 0.79-1.16)。
- 他汀未增加肝脏相关危害风险(RR 1.10,95%CI 0.90-1.35)。
- 汇总分析中他汀与糖尿病风险无显著关联(RR 1.05,95%CI 0.91-1.20;I²=52%),但1项试验发现高强度他汀与糖尿病风险增加相关(RR 1.25,95%CI 1.05-1.49)。
- 无试验直接比较滴定与固定剂量他汀,他汀强度间无明确差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 汇总分析中糖尿病风险存在统计异质性(I²=52%)。
- 无试验直接比较滴定与固定剂量他汀。
- 他汀强度间无明确差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy. OBJECTIVE: To systematically review benefits and harms of statins for prevention of CVD to inform the US Preventive Services Task Force. DATA SOURCES: Ovid MEDLINE (from 1946), Cochrane Central Register of Controlled Trials (from 1991), and Cochrane Database of Systematic Reviews (from 2005) to June 2016. STUDY SELECTION: Randomized clinical trials of statins vs placebo, fixed-dose vs titrated statins, and higher- vs lower-intensity statins in adults without prior cardiovascular events. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: All-cause mortality, CVD-related morbidity or mortality, and harms. RESULTS: Nineteen trials (n = 71 344 participants [range, 95-17 802]; mean age, 51-66 years) compared statins vs placebo or no statin. Statin therapy was associated with decreased risk of all-cause mortality (risk ratio [RR], 0.86 [95% CI, 0.80 to 0.93]; I2 = 0%; absolute risk difference [ARD], -0.40% [95% CI, -0.64% to -0.17%]), cardiovascular mortality (RR, 0.69 [95% CI, 0.54 to 0.88]; I2 = 54%; ARD, -0.43% [95% CI, -0.75% to -0.11%]), stroke (RR, 0.71 [95% CI, 0.62 to 0.82]; I2 = 0; ARD, -0.38% [95% CI, -0.53% to -0.23%]), myocardial infarction (RR, 0.64 [95% CI, 0.57 to 0.71]; I2 = 0%; ARD, -0.81% [95% CI, -1.19 to -0.43%]), and composite cardiovascular outcomes (RR, 0.70 [95% CI, 0.63 to 0.78]; I2 = 36%; ARD, -1.39% [95% CI, -1.79 to -0.99%]). Relative benefits appeared consistent in demographic and clinical subgroups, including populations without marked hyperlipidemia (total cholesterol level <200 mg/dL); absolute benefits were higher in subgroups at higher baseline risk. Statins were not associated with increased risk of serious adverse events (RR, 0.99 [95% CI, 0.94 to 1.04]), myalgias (RR, 0.96 [95% CI, 0.79 to 1.16]), or liver-related harms (RR, 1.10 [95% CI, 0.90 to 1.35]). In pooled analysis, statins were not associated with increased risk of diabetes (RR, 1.05 [95% CI, 0.91 to 1.20]), although statistical heterogeneity was present (I2 = 52%), and 1 trial found high-intensity statins associated with increased risk (RR, 1.25 [95% CI, 1.05 to 1.49]). No trial directly compared titrated vs fixed-dose statins, and there were no clear differences based on statin intensity. CONCLUSIONS AND RELEVANCE: In adults at increased CVD risk but without prior CVD events, statin therapy was associated with reduced risk of all-cause and cardiovascular mortality and CVD events, with greater absolute benefits in patients at greater baseline risk.
引用
- Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016. PMID: 27838722. doi:10.1001/jama.2015.15629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。